LIB Therapeutics

Focus: LIB Therapeutics is a public biotech company founded in 2015 and headquartered in Cincinnati, Ohio, focused on developing oral and injectable small molecules for cardiovascular and metabolic diseases.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About LIB Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow LIB Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

9 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LIB003

Hypercholesterolemia

Phase 1

Clinical Trials (1)

NCT03545438Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

Phase 1

Help build intelligence for LIB Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Substantial Phase 3 pipeline with 9 active programs, predominantly focused on hypercholesterolemia and cardiovascular indications with near-term catalysts
Public company status provides liquidity and established infrastructure compared to private biotech
Lead program lerodalcibep in advanced development across multiple cardiovascular indications suggests multiple potential near-term approvals

Watch Out For

Zero active job openings at time of data collection indicates potential hiring freeze or minimal expansion
Limited publicly available financial, cash position, and R&D spend data raises transparency concerns for career planning

Generated by Claude from LIB Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LIB003

LDL Cholesterol

Phase 2

Clinical Trials (1)

NCT03549260Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

Phase 2

LIB003

Hypercholesterolemia

Phase 2

Clinical Trials (1)

NCT03847974Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

Phase 2

lerodalcibep

Hypercholesterolemia

Phase 3

Clinical Trials (1)

NCT04790513Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

Phase 3

lerodalcibep 300 mg Monthly SC

Familial Hypercholesterolemia - Heterozygous

Phase 3

Clinical Trials (1)

NCT07102511Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

Phase 3

lerodalcibep

Homozygous Familial Hypercholesterolemia

Phase 3

Clinical Trials (1)

NCT04034485Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Phase 3

lerodalcibep

Cardiovascular Diseases

Phase 3

Clinical Trials (1)

NCT04797247Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction